Tagged Articles

Bayer 249 articles

Beasley Allen is one of a dozen firms leading Xarelto side effects litigation


Twelve plaintiff law firms from various parts of the country are involved in Xarelto side effects litigation, including Alabama law firm Beasley Allen. More than 9,000 lawsuits have been filed across the country against Johnson & Johnson, Janssen Pharmaceuticals, Bayer, and their related companies over claims that the top-selling blood thinner Xarelto, known chemically as rivaroxaban, caused bleeding injuries including gastrointestinal bleeds, brain hemorrhages and bleeding deaths. More than 7,000 of the lawsuits are in Louisiana, approximately 1,000 are on file in state court in Philadelphia, and an additional 1,000 are in Delaware. U.S. District Court Judge Eldon Fallon, who ... Read More

Number of Xarelto lawsuits growing


Patients who require blood-thinning medications to treat or prevent blood clot-related health conditions should discuss with their doctors the risks and benefits of the various types of treatments, advised Dr. Rita Redberg, a professor of cardiology at the University of California, San Francisco. “There are now several new oral anticoagulants and we don’t have a lot of studies that compare one to the other,” she said. Millions of patients are diagnosed with the heart rhythm abnormality atrial fibrillation, and most are treated with blood thinners to prevent strokes. For decades, doctors have prescribed warfarin. But patients taking the drug require ... Read More

Xarelto makers allegedly knew monitoring device used in clinical trials was flawed


Johnson & Johnson’s Janssen Pharmaceuticals and Bayer allegedly knew that a device used to monitor the blood thinning effects of medication given patients during clinical trials for the companies’ anticoagulant Xarelto was unreliable but kept mum about the issue to the study’s monitors and drug regulators, the British Medical Journal (BMJ) reports. Concerns about the accuracy and reliability of the INRatio device used in a pivotal trial studying the safety and efficacy of Xarelto was brought into question in 2008 by investigators. Janssen responded by setting up a safety recheck program. But the company didn’t provide that data with the trial’s monitoring ... Read More

Judge extends deadline for filing Xarelto lawsuits


The deadline for filing Xarelto lawsuits alleging bleeding injuries with the popular blood thinner has been extended 90 days for certain plaintiffs groups due to an influx of complaints that have reportedly inundated the clerk’s office, Judge Eldon Fallon ordered. Johnson & Johnson subsidiary Janssen Pharmaceuticals and Bayer are facing more than 7,000 lawsuits in a multidistrict litigation alleging the companies’ blood thinner Xarelto caused major bleeding events including gastrointestinal bleeds and brain hemorrhages. Four bellwether trials have already been scheduled for 2017. Another 950 lawsuits have been consolidated into a mass tort program in Pennsylvania with the first scheduled ... Read More

Xarelto antidote saves lives during bleeding emergency but not yet on market


An experimental drug quickly reverses the bleeding effects of new blood thinning medications to help save lives in the event of a bleeding emergency, but the medication is not yet on the market. Portola Pharmaceuticals was ready to launch AndexXa, known generically as andexanet alfa once it got Food and Drug Administration (FDA) approval last month. But the FDA said it couldn’t approve the medication without more data and information on its manufacturing practices. The news was a blow to investors who were banking on sales of Johnson & Johnson’s Janssen Pharmaceuticals and Bayer top selling blood thinner Xarelto to jump once ... Read More

Experimental diabetes drug may increase ketoacidosis risk


Sanofi and Lexicon have teamed up on the development of a new diabetes drug that can treat both type 1 diabetes and type 2 diabetes. The new medication, known chemically as sotagliflozin, is in a class of diabetes drugs known as SGLT2 inhibitors, which also includes the brand name medications Invokana, Invokamet, Farxiga and Jardiance. Most type 2 diabetes medications work through the pancreas and liver. SGLT2 inhibitors work differently, blocking the absorption of glucose in the kidneys, allowing patients to excrete excess glucose through their urine. Sotagliflozin also works by targeting SGLT1 inhibitors located in the intestinal tract. SGLT2 ... Read More

Reader concerned about Xarelto bleeding side effects


“After having a pacemaker fitted, I was prescribed 20mg Xarelto (rivaroxaban),” a Daily Mail reader wrote in a message to Martin Scurr for the “Ask the Doctor” column. “I have read it was described as ‘the most dangerous drug,’ and that thousands are suing the makers. I am healthy but terrified about adverse reports.” Xarelto is in a new class of blood thinners. It is used to prevent strokes in patients with the heart condition atrial fibrillation. It is also used to treat deep vein thrombosis and pulmonary embolism, and to prevent blood clots in patients who have recently undergone ... Read More

Wrongful death lawsuit blames blood thinner Xarelto


New Jersey resident Dell Wise is suing Johnson & Johnson, Janssen Pharmaceuticals, Bayer, and their related companies over allegations that the drug companies’ blood thinner Xarelto caused the death of her aunt, Mattie Edgin, The lawsuit accuses the drug companies of acting negligently by “fervently” marketing Xarelto “with no regard to the accuracy and misrepresentations of their misleading advertisement,” citing studies that link the anticoagulant to serious bleeding events including gastrointestinal bleeds, brain bleeds, and bleeding deaths. “Due to the defective nature of Xarelto, persons who were prescribed and ingested Xarelto, for even a brief period of time, including the ... Read More

Xarelto litigation gaining momentum nationwide


Litigation involving the blood thinner Xarelto is gaining momentum nationwide. There has been an increase in filings to the multidistrict litigation (MDL), and the first trial dates are soon to be scheduled in the mass tort program in Philadelphia. The Xarelto MDL increase comes just weeks after Judge Eldon E. Fallon of the Eastern District of Louisiana issued an order to extend deadlines another 90 days for certain plaintiffs groups to serve Bayer with complaints. The order came about “due to an influx of complaints” that reportedly inundated the clerk’s office. The first bellwether trials in the Xarelto MDL have ... Read More

FDA approves Bayer’s study plan for tracking Essure side effects


The Food and Drug Administration (FDA) has given the go-ahead to Bayer’s updated post-market surveillance study plan for its non-surgical permanent birth control device Essure. The controversial contraceptive has been linked to tens of thousands of adverse events including allergic reactions, autoimmune reactions, unintended pregnancies, miscarriages and fetal deaths, and four cases of adult death. The device can also migrate from its intended position in the fallopian tubes and damage neighboring tissue and organs. Essure, made by Bayer and approved for marketing in the U.S. in 2002, consists of two nickel alloy coils that are inserted into the fallopian tubes ... Read More